Published in Hepatitis Weekly, March 26th, 2001
R.Z. Yu and colleagues at Isis Pharmaceuticals in California established the likely pharmacologic activity of ISIS 22023, a modified phosphorothioate antisense oligonucleotide, in a paper published in the Journal of Pharmacology and Experimental Therapeutics.
"We characterized the relationships in mice between total dose administered, dose to the target organ, and ultimately, the intracellular concentration within target cell types to the...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Hepatitis Weekly
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.